ROCKVILLE, MD -- (Marketwire) -- 11/28/12 -- MarketResearch.com has announced the addition of "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth," to their collection of market research reports.

GBI Research, a leading business intelligence provider, has released its latest research, "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth." The report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV/AIDS therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the market for HIV/AIDS therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report provides branded and generics segmentation in the therapeutic landscape segment. In addition, it analyzes the HIV/AIDS therapeutics market in India, China and Australia. The report discusses the global pipeline for all the HIV/AIDS molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research found that the HIV/AIDS therapeutics market in the top seven markets was valued at $13.5 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 12.5% during the 2004-2011 historic period. The market is projected to witness growth of 7% during the 2011-2018 forecast period to reach $21.8 billion. The growth is primarily driven by the increase in the use of single dose multi-class combination drugs such as Atripla, Complera. With the recent launch of Stribild (previously known as Quad), the multi-class combination drugs would drive the market.

For more information, visit http://www.marketresearch.com/land/product.asp?productid=7223993&progid=84973

Follow us on Facebook
Follow us on Twitter

About GBI Research

GBI Research provides industry-leading global business intelligence solutions. Our products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports per annum across a wide range of industries. Our reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from our expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia.

About MarketResearch.com

MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com's Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Cindy Frei at 240.747.3014 or visit http://www.marketresearch.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine